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To combat the growing threat posed by antimicrobial resistance (AMR), there is an urgent need to discover new mode-of-action (MOA) antibiotics that can overcome pre-existing antibiotic resistance mechanisms.
1, 2 The bacterial cell membrane is an essential macromolecular structure that plays a critical role in cellular respiration and in the transport of nutrients and is therefore a promising target for the development of new antibiotics. In addition, it is anticipated that antibiotics that target the intrinsic structure of the bacterial cytoplasmic membrane, rather than having a proteinogenic-target, cannot be easily countered through simple point mutations and would thus exhibit low resistance frequencies. However, only a handful of clinically used antibiotics are known to employ this general MOA (e.g. telavancin and daptomycin). [3] [4] [5] [6] [7] The study of antibiotics that interfere with the bacterial cytoplasmic membrane in novel ways is therefore a key area for the development of new antimicrobials refractory to the emergence of resistance.
Vancoresmycin is a structurally unique, large tetramic acid containing polyketide natural product (from 0.4 to 0.5-0.7 g/mL). 9 Transcriptional profiling of the resultant mutants revealed that the differentially expressed genes mainly encode for proteins which associate or depend on the cytoplasmic membrane for activity.
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We have used a wide range of methods to study the mode of action of vancoresmycin and propose that it targets the cytoplasmic membrane of Gram-positive bacteria via a non-pore forming, concentration-dependent depolarization mechanism. To facilitate future development of such a highly complex polyketide natural product, we have also identified and heterologously expressed the biosynthetic gene cluster in Streptomyces coelicolor M1152. Analysis of the gene sequence suggests a probable pathway for the biosynthesis of vancoresmycin. Figure S1 and Supporting Table S2 ).
RESULTS AND DISCUSSION

Isolation of vancoresmycin from
Vancoresmycin is a potent and selective antibiotic towards Gram-positive pathogenic bacteria.
Vancoresmycin was tested against a panel of 25 clinically relevant Gram-positive pathogens, including 15 antibiotic-resistant isolates (Supporting Table S3 ). Low MICs were observed against 11 MRSA strains (0.25 -0.5 µg/mL) and 10 VRE strains (0. 
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. Therefore, this result was consistent with a MOA resulting in an increase in cell envelope stress ( Figure 2 ).
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Vancoresmycin does not act on the bacterial cell wall. The lack of a cell wall makes L-form strains an interesting model to probe the mode of action of an antibiotic, as compounds that specifically act on cell wall peptidoglycan synthesis or its assembly should not inhibit the proliferation of L-forms. 19 We therefore compared the sensitivity of walled and L-form B. subtilis strains to vancoresmycin, to control compounds carbenicillin (cell wall) and nalidixic acid (NAL, gyrase inhibitor), and to carbonyl cyanide m-chlorophenyl hydrazine (CCCP, protonophore) ( Table 1 ). As expected, carbenicillin was active only on walled cells because it inhibits cell wall assembly. In contrast, vancoresmycin showed similar activity against both B. subtillis strains, as did CCCP and NAL, thus ruling out the cell wall synthetic machinery as the principal cellular target of vancoresmycin.
Vancoresmycin targets the cytoplasmic membrane. Next, we examined the ability of vancoresmycin to interfere with the integrity of the cytoplasmic membrane, through use of the voltage sensitive dye DiSC3(5). DiSC3(5) accumulates in well-energized cells, resulting in a quenching of overall fluorescence in the cell suspension. Antibiotics that lead to an increased membrane ion-permeability and, consequently, to a dissipation of membrane potential, trigger a release of the dye into the surrounding medium. This release can be measured as fluorescence dequenching. 20 The ability of vancoresmycin to cause membrane depolarization was tested both at sub-lethal and lethal concentrations (Supporting Figure S3 ). Even at the highest concentration, no complete membrane depolarization was observed. Instead, the depolarization was gradual, concentration-dependent, and incomplete ( Figure   3 ). These results indicate that vancoresmycin indeed depolarizes the cytoplasmic membrane to a degree that is sufficient to explain the growth inhibition. However, the observed gradual and partial depolarization is seemingly inconsistent with pore formation, ruling it out as the molecular mechanism by which vancoresmycin kills.
Single cell analysis of membrane depolarization and pore formation. The use of depolarization kinetics to rule out pore-formation in vivo has a commonly overlooked caveat: a significant cellular heterogeneity giving full depolarization of a subset of cells, could cause partial depolarization erroneously interpreted as non-pore forming activity. To test this, we developed a microscopic singlecell assay which combines both the voltage-sensitive dye DiSC3(5), and Sytox Green, a membrane impermeable DNA stain commonly used as a reporter for pore formation (Figure 4) . 21 Upon addition of nisin, which assembles into large non-specific pores in the cytoplasmic membrane, a bright Sytox
Green staining and a simultaneous homogeneous loss of DiSC3(5)-fluorescence was observed, consistent with membrane depolarization caused by pore formation. 16 In comparison, addition of gramicidin, which forms small cation-specific channels, triggered full and homogeneous depolarization without Sytox Green staining. 22 In contrast to both of these control antimicrobials, vancoresmycin triggered a strikingly heterogeneous dissipation of membrane potential. Crucially, individual cells exhibited partial depolarization levels, thus ruling out pore formation as a mode of action for vancoresmycin. Moreover, no significant uptake of Sytox Green was observed in vancoresmycintreated cells, again inconsistent with pore formation. Based on these data, we conclude that vancoresmycin kills bacteria by membrane depolarization but does not utilize the common mechanisms of pore or cation-selective channel-formation. Rather, we propose that vancoresmycin causes depolarization by perturbing the membrane bilayer integrity and thereby its tight barrier function. Formally, however, we cannot yet rule out a mode of action based on vancoresmycin acting as an ion carrier. Rather than depolarising the membrane through bilayer perturbations, the observed gradual reduction of membrane potential could also be due to specific inhibition of the respiratory chain. Indeed, a concentration-dependent reduction of B. subtilis respiration is observed upon incubation with vancoresmycin (Supporting Figure S5) . However, the respiratory chain of B. subtilis requires membrane potential for proper activity 23, 24 and the observed inhibition could, thus, be a consequence rather a cause for the depolarization. Since vancoresmycin retains strong antibacterial activity against both streptococci and enterococci that do not encode a TCA-cycle or a classical respiratory chain, we strongly favour the former option.
Heterologous expression of vancoresmycin. Future development of vancoresmycin would likely involve deriving a structure activity relationship via a range of molecular analogues. However, the large and complex structure of vancoresmycin presents an extreme challenge for chemical synthesis.
Therefore, the production of analogues would be reliant on either semi-synthetic modification of the natural product, requiring access to large quantities of material from a reliable heterologous production host, or through genetic manipulation of the biosynthetic cluster. Thus, to facilitate these future studies, we developed a heterologous expression system for vancoresmycin. To test whether this cluster was responsible for the production of vancoresmycin, a high-molecularweight P1 artificial chromosome (PAC) library was obtained consisting of 2,688 strains with an average insert size of 138 kb, by BioS&T Inc. (detailed information in SI). The entire library was screened by PCR using primers designed to amplify genes located at the start, middle and end of the proposed cluster (var1, var14, var+1). PCR screening identified a single PAC (3-3B9) which had the correct PCR profile. This PAC was cloned into S. coelicolor M1152 by intergeneric conjugation and production of antibiotic activity was analysed by plug assay. Of the 15 exconjugants obtained, 9 produced an inhibition zone and the expected blue (LacZ + ) reporter gene halo using the B. subtilis LiaRS reporter strain. Culture supernatant of a typical ex-conjugant was semi-purified by SPE and HPLC and subsequently analysed via LC-MS, giving a peak at 9.5 min identical to the mass of vancoresmycin ( Figure 5 ).
This peak was present in extracts from the Amycolatospis parent strain DEM30355 but absent from those of the M1152 host strain. The fragmentation pattern of this peak in positive and negative MS mode was consistent with previously reported vancoresmycin data, confirming that PAC 3-3B9 encodes all the genes necessary for production (Supporting Figure S7 and Supporting Figure S8 ).
Additional peaks present in M1152::PAC3-3B9 were, due to their molecular weight, fragmentation pattern and absence in the native host strain, proposed to be intermediates in biosynthesis or shunt metabolites (Supporting Figure S9 ).
To confirm the sequence of the gene cluster producing vancoresmycin, the heterologous host M1152::PAC3-3B9 was sequenced using Illumina MiSeq and found to contain a 184 kb insert which contained Cluster 13. At 141 kb, the vancoresmycin biosynthetic gene cluster is, to our knowledge, the largest antibiotic gene cluster heterologously expressed to date.
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Gene cluster assignment and proposed biosynthetic pathway. The, 141 kb pks1/nrps, vancoresmycin biosynthetic gene cluster contains thirty eight genes. Including eight type1 pks genes that span the majority (108 kb) of the cluster (Figure 6a ). BlastP analysis identified the remaining genes as being involved in peptide biosynthesis, late stage tailoring reactions and mycosamine biosynthesis (Supporting Table S4 ). Sequence domain analysis of the eight type1 pks genes revealed a total of 101 enzymatic domains organised into 23 modules (Figure 6b) 
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, with a single non-functional ketoreductase (KR) in module 11. We propose the biosynthesis of the polyketide component of vancoresmycin starts at var13 through the loading of an isobutyrate unit, followed by condensation of 10 malonyl-CoA and 13 methylmalonyl-CoA units.
Based on analogy to previous studies examining the biosynthesis of tetramic acid containing natural products in both bacteria 27, 28 and fungi
29, 30
, we suggest that the tetramic acid moiety is derived from leucine 31 which is N-methylated by methyltransferase (var17), condensed with the polyketide backbone (mediated by either var16 or var31), and finally cyclised (potentially mediated by var18). 32 Subsequent tailoring steps and putative enzymes include: (1) hydroxylation of C-26 (var19); (2) attachment of mycosamine (var24 or var32); (3) a non-enzymatically controlled ketoenol tautomerisation; (4) reduction of the tetramic acid side chain (var14). The absolute stereochemistry of vancoresmycin is unknown, but we can propose a stereochemical assignment based on domain analysis of the KR domains ( Figure 6C ).
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CONCLUSIONS
In summary, we propose that the primary MOA of vancoresmycin involves a non-pore-forming depolarization of the bacterial membrane and we speculate that vancoresmycin causes this depolarization by perturbing the membrane bilayer integrity. To aid future development of this antibiotic, a heterologous expression system for biosynthetic cluster of vancoresmycin was constructed in S. coelicolor M1152. At 141 kb, it may be the largest gene cluster to be expressed in a surrogate host and is to our knowledge the first heterologously produced antibiotic from the genus Amycolatopsis. This study will hopefully pave the way for future development of vancoresmycin derivatives and other antibiotics from the genus Amycolatopsis. Vancoresmycin was prepared at a stock concentration of 10 mg/mL in 100% DMSO, which was tested in Mueller-Hinton broth at a concentration range of 0.004 to 4 µg/mL, and inoculated with a final concentration of 5 x 10 5 CFU/mL of each isolate. An inhibitor-free control was also included.
MATERIALS AND METHODS
Incubation occurred at 37 ± 0.5 °C for 18 h.
The MIC was defined as the lowest concentration of vancoresmycin inhibiting growth after overnight incubation and determined spectrophotometrically at 640 nm. A spectrophotometric reading of ≤0.01, after deduction of the background absorbance, was the cut-off for inhibition. All suspensions showing inhibition were subcultured onto blood agar and incubated for 18 h at 37 ± 0.5 °C. Colony counts were compared to a cut-off for bactericidal activity, determined using the calculation: initial inoculum x aliquot plated x allowable viable percent. The minimum bactericidal concentration (MBC) was defined as the lowest vancoresmycin concentration eliciting bactericidal activity after subculture onto an antibiotic-free medium.
Reporter strain panel. A Kirby-Bauer disc diffusion assay was performed with the B. subtilis reporter strain panel, gyrA, ypuA, fabHA, ɸ105, helD and liaI [12] [13] [14] . The nutrient agar was supplemented with XGal (100 μg/mL).
Inhibition assay against cell wall deficient bacteria (L-form).
Rod shaped cells were maintained in NB supplemented with 1 mM ITPG while the L-form strain was maintained in NB/MSM as previously reported.
19
The antibiotics nalidixic acid, CCCP, vancoresmycin and carbenicillin were diluted in NB/MSM. The to obtain a baseline, followed by addition of vancoresmycin in final concentrations of 200 ng/mL, 100 ng/mL, 50 ng/mL, and 25 ng/mL. Fluorescence measurements were taken every minute with a Fluostar
Optima fluorimeter (BMG) using 610/10 nm excitation, and 660/10 emission filters.
DiSC3 (5) and Sytox Green combined microscopy. B. subtilis 168CA was grown to an OD600 of 0.2 in LB medium at 37 °C while shaking, followed by simultaneous staining with 2 μM DiSC3(5) and 50 nM Sytox Green for 5 min at 37 °C. The ability vancoresmycin to depolarize individual cells and to trigger influx of Sytox Green as an indication for pore formation, were assayed by addition of vancoresmycin to a final concentration of 100 ng/mL for 1 min, followed by transfer to microscopy slides covered with 1.2% agarose in water and fluorescence imaging. As a positive control for channel-mediated depolarization without pore formation, cells were incubated for 1 min with gramicidin (mix of gramicidin A, B, C, and D, final concentration of 5 μg/mL). In brief, B. subtilis 168CA was grown to an OD600 of 0.2 in LB medium at 37 °C while shaking, followed by transfer to a microtiter plate as 100 µl aliquots, and incubation with 5 µl of the alamarBlueT DNA sequencing and bioinformatic analysis. High molecular chromosomal DNA of Amycolatopsis DEM30355 was extracted according to standard procedures. 34 DNA sequencing was performed using Pacific Biosciences (PacBio) and Illumina (GATC) technology. Contigs were assembled using the SMRT portal of PacBio. The annotation of open reading frames (ORFs) and assignment of putative gene functions were done using a combination of RAST and blastP. 35, 36 Putative NP-encoding gene clusters were identified using antiSMASH3.
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The nucleotide sequence of the vancoresmycin cluster was deposited in the NCBI database with the accession number (will be submitted upon acceptance). several genes across the full length of the cluster (see Supporting Table S6 for targets and primer sequences). PCR amplification was performed using Herculase II Fusion according to manufacturer's protocols. This resulted in one PAC clone (3-3B9) being identified which was transferred together with pR9604 into E.coli ET1256. We subsequently conjugated the plasmid pEASAC13_3-3B9 into S.
coelicolor M1152 as described previously. 
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